QTI

QT Imaging Holdings, Inc. (QTI) - Q2 2024 10-Q Summary

Business Context and Reporting Period

This report covers the quarterly period ended June 30, 2024. QT Imaging Holdings, Inc. is a medical device company developing body imaging systems using low-frequency sound waves, with its initial product being the QT Breast Scanner. The company completed a business combination with GigCapital5, Inc. on March 4, 2024, resulting in a reverse recapitalization and a name change. The company is classified as an emerging growth company and a smaller reporting company.

Key Financial Metrics

Note: Net Loss Attributable to Common Stockholders includes a non-cash deemed dividend of $5,185,502 related to warrant modifications.

Material Changes vs. Prior Period

• Revenue Growth: Revenue increased significantly from $3,183 in Q2 2023 to $1.71 million in Q2 2024, driven by the sale of four QT Breast Scanners. YTD revenue reached $3.08 million compared to $10,747 in the prior year.
• Operating Expenses: Total operating expenses rose to $3.09 million in Q2 2024 from $1.20 million in Q2 2023. This increase is attributed to higher employee compensation, professional services, and insurance costs, as well as non-recurring transaction expenses related to the business combination.
• Debt and Financing: The company secured significant liquidity through the business combination, including a $10 million Pre-Paid Advance from Yorkville and a $1.5 million loan from Cable Car. Cash on hand increased from $184,686 at year-end 2023 to $4.6 million at June 30, 2024.
• Non-Cash Items: Significant non-cash gains were recorded due to changes in the fair value of derivative liabilities ($1.73 million gain in Q2) and earnout liabilities ($310,000 gain in Q2), offsetting operating losses.

Guidance, Outlook, and Risks

• Liquidity Outlook: Management believes current cash and financing arrangements (including a Standby Equity Purchase Agreement with Yorkville for up to $40 million additional capital) are sufficient to fund operations for at least the next 12 months.
• Commercialization: The company entered into a Distribution Agreement with NXC Imaging, Inc. (a subsidiary of Canon Medical Systems) on June 18, 2024, appointing NXC as the exclusive reseller in the U.S. and territories. A feasibility study with Canon Medical Systems in Japan is underway to explore an OEM agreement.
• Earnout Milestones: The company has contingent earnout obligations tied to FDA clearances, revenue targets (e.g., $4.4M in 15 months, $17.1M in 2025), and device placements. Failure to meet these could impact future equity issuance.
• Risks: Key risks include the company's history of net losses, dependence on a limited number of customers (NXC accounted for 38% of Q2 revenue), the need for additional capital to achieve profitability, and the uncertainty of regulatory approvals for new indications or products.
• Internal Controls: The company identified material weaknesses in internal controls over financial reporting related to segregation of duties and technical accounting aspects of material transactions. Remediation efforts are underway.

Investor Verification Checklist

• Customer Concentration: Verify the stability of the relationship with NXC Imaging, which represents a significant portion of revenue and is the exclusive U.S. reseller.
• Debt Covenants and Triggers: Review the terms of the Yorkville Pre-Paid Advance and Cable Car Loan, specifically the conversion triggers and interest rate escalation clauses upon default.
• Earnout Liability Valuation: Assess the assumptions used in the Monte Carlo simulation for the $750,000 earnout liability, particularly regarding revenue forecasts and FDA clearance probabilities.
• Warrant Liability: Monitor the fair value of the warrant liability ($18,588) and derivative liability ($408,100), as fluctuations in stock price will directly impact reported earnings.
• Remediation of Internal Controls: Track the progress of remediation for the identified material weaknesses in internal controls over financial reporting.